Across the clinical studies covered by a review, model-informed precision dosing, or MIPD, software outperformed conventional methods on predictive accuracy, precision and pharmacokinetic target attainment. In plain terms, the tools were better at estimating and reaching the intended level of drug exposure. The finding concerns how doses performed against drug targets, not whether children had better health outcomes.
The review covered 26 clinical studies enrolling more than 4,000 pediatric and neonatal patients. It did not report the exact total number of patients or the sample size of each study, which makes the overall scale clear while leaving the contribution of individual studies difficult to assess from the available summary.
A varied software market, without a declared winner
Reviewers identified 11 available MIPD platforms and reported differences in how they were deployed, the model libraries they contained, the drugs they covered, their electronic health-record integration and their regulatory status. The review mapped those differences without providing a platform-level ranking.
To qualify, a tool had to use Bayesian forecasting and include at least one pediatric module. Eligible tools were identified through iterative searches and verification with developers. For eligible platforms, the review summarized PubMed-indexed pediatric clinical studies by study design, population, drug, clinical decision-support objective and findings.
The article also uses a representative bedside tutorial with NextDose for neonatal vancomycin dosing. That example was part of the review's broader aim to map bedside-compatible tools and synthesize clinical evidence in pediatric and neonatal populations.
The reported gains were mainly pharmacokinetic
The reported gains were in pharmacokinetic measures, or measures of how drug exposure matched a target, rather than in direct patient outcomes. Across the studies, MIPD consistently performed better than conventional methods for predictive accuracy, precision and target attainment. The review did not report pooled numerical effect sizes, confidence intervals, p values or absolute risks, so it is not possible to judge the size of the advantage from the summary alone.
One specific measure was area-under-the-curve target attainment. Area under the curve describes a drug's exposure over time, so reaching its target means exposure reached the intended level. The review reported significant improvements in this measure for key drugs such as vancomycin, but did not give the size of the improvement, the number of patients who reached target or a quantitative measure of uncertainty.
The review also reported workflow benefits. These included reduced sampling burden and faster therapeutic exposure, predominantly for antibiotics and selected chemotherapeutics such as busulfan. The review did not provide drug-specific estimates or uncertainty measures, so their size cannot be determined from the available evidence.
Promising, but not yet a patient-outcome story
The authors interpret the synthesis as showing substantial potential for MIPD software to improve precision dosing in pediatrics, citing superior target attainment and operational advantages. But the evidence does not extend to direct patient-centered outcome data, and the authors identify prospective randomized comparisons with conventional dosing as a gap.
They also identify gaps in cost-effectiveness analyses, clinician-training evidence and validation or expansion for non-antibiotic drugs. Those omissions leave unanswered whether better pharmacokinetic performance translates into outcomes patients notice, whether the approach offers value for health systems, and how broadly it can be used across pediatric medicines.
For now, the evidence supports a narrower conclusion: the reviewed studies link MIPD with better dosing-target performance and some workflow advantages, particularly in antibiotic studies and selected busulfan use. They do not establish better patient-centered outcomes, cost-effectiveness or performance across all pediatric drugs and settings.
Paper data and sources
Original title: Model-Informed Precision Dosing in Pediatric Patients: Current Software Tools and Bedside Guided Application.
Authors: Abdullah Aljutayli, Emna Gaies, Mohammed S Alasmari et al.
Journal/Repository: Paediatric drugs
Status: Peer-reviewed
First online: 2026-08-21
DOI: 10.1007/s40272-026-00763-4
Original paper · Full text